Avantax Advisory Services Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,483 shares of the medical research company's stock after selling 1,529 shares during the quarter. Avantax Advisory Services Inc.'s holdings in IQVIA were worth $1,667,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in IQVIA in the 4th quarter valued at $236,120,000. FMR LLC grew its position in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of IQVIA in the 3rd quarter worth $147,683,000. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after buying an additional 583,396 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Institutional investors own 89.62% of the company's stock.
Analyst Ratings Changes
IQV has been the subject of several research reports. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price for the company. Robert W. Baird lowered their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. Citigroup lowered their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Morgan Stanley raised their price objective on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $249.05.
Get Our Latest Stock Report on IQVIA
IQVIA Stock Performance
IQV stock traded up $1.59 during trading on Friday, hitting $185.85. 3,242,587 shares of the company traded hands, compared to its average volume of 1,471,529. The stock's 50-day simple moving average is $195.30 and its 200 day simple moving average is $209.18. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $32.77 billion, a PE ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $254.80.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
